Publication
Giredestrant plus Everolimus in Advanced Breast Cancer.
Erica L Mayer, Sara M Tolaney, Miguel Martín, Gregory A Vidal, Luca Moscetti, Komal L Jhaveri, Adam Brufsky, William J Gradishar, Andreas Schneeweiss, Naoki Niikura, Anne Favret, Margarita Alfie, Keun Seok Lee, Sarah Khan, Merilin B Feldman, Bann-Mo Day, Lisa H Lam, Walter C Darbonne, Mona D Shah, Kristin L Griffiths, Gillian DiLallo, Pablo D Pérez-Moreno, Hope S Rugo, evERA Breast Cancer Investigators
- Source
- PubMed
- Retrieved
- Oct 1, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20261001-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Giredestrant and everolimus target the estrogen receptor (ER) pathway and the phosphatidylinositol 3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway, respectively, which are implicated in endocrine-therapy resistance. METHODS: In this phase 3,…
Read on PubMedLinked entities
Linked entities (2)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT05306340registry_reference1.00
Candidate 1
- cancerMalignant Breast Neoplasmdictionary0.60
Registered trialsNCT05306340
Curated evidence
Evidence citing this paper (0)
Data not yet available